Kidney Week

Abstract: FR-PO1039

Cytokine Release Syndrome Following Thymoglobulin Induction in a Kidney Transplant Recipient with Lupus Nephritis: A Case Report

Session Information

• Transplantation: Clinical - Pharmacology and Nonkidney Solid Organ Transplants
  November 07, 2025 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Transplantation

• 2102 Transplantation: Clinical

Authors

• Tamimi, Basel Emad M.H, Tulane University School of Medicine, New Orleans, Louisiana, United States

Basel Emad M.H Tamimi, MD

• Alqussairy, Saddam, Tulane University School of Medicine, New Orleans, Louisiana, United States

Saddam Alqussairy, MD

• Sharshir, Moh'd, Tulane University School of Medicine, New Orleans, Louisiana, United States

Moh'd Sharshir, MD

• Baudy, Adrian J., Tulane University School of Medicine, New Orleans, Louisiana, United States

Adrian J. Baudy, MD, MBA

Group or Team Name

• Tulane Nephrology.

Introduction

Cytokine release syndrome (CRS) is a rare but potentially life-threatening complication of antithymocyte globulin (ATG) therapy. Although well described in hematologic malignancies and immunotherapy, CRS remains underrecognized in solid organ transplantation. We present a case of CRS following ATG induction in a young woman with lupus nephritis undergoing deceased donor kidney transplantation.

Case Description

A 22-year-old female with end-stage kidney disease from class IV lupus nephritis underwent deceased-donor kidney transplantation. Induction included rabbit-derived Thymoglobulin (1.5 mg/kg), methylprednisolone, and diphenhydramine. Following successful transplantation and extubation, she developed acute respiratory distress, fever (38.1 C), hypoxia (< 92%), hypotension (78/35 mmHg), and tachycardia (HR 112 bpm). Initial treatment with IV epinephrine and diphenhydramine failed to improve symptoms. The patient was reintubated for respiratory failure, requiring vasopressors and mechanical ventilation support.

Bedside echocardiography showed biventricular dilation with an ejection fraction <15%. Labs revealed lactic acidosis (25.1 mmol/L), leukocytosis (21.1 x10³/μL), IL-6 (1,047 pg/mL), CRP (11.2 mg/dL), and ferritin >15,000 ng/mL. Infectious workup, including cultures and imaging, was negative. The diagnosis of grade 4 CRS was established based on fever, hypotension requiring multiple vasopressors, and intubation. She was placed on veno-arterial ECMO, dobutamine, and continuous renal replacement therapy (CRRT) for delayed graft function.

Treatment included a single dose of tocilizumab (IL-6 receptor blocker) and two doses of basiliximab for the kidney transplant. Eventually, the patient’s condition improved, with inflmatory markers trending downwards, and kidney function improving, prompting decannulation of ECMO and cessation of renal replacement therapy. She was discharged home with stable graft function, with Cratinine 1.2 mg/dL

Discussion

This case helps illustrate the importance of recognizing CRS as a potential differential diagnosis in transplant recipient patients who present with systemic inflammatory response after ATG. CRS can be mistaken for acute rejection, but early recognition and prompt management, favor better outcomes.

Digital Object Identifier (DOI)

• doi: 10.1681/ASN.2025ncn0pssh